Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

The findings suggest -- for the first time in a clinical trial -- that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of Alzheimer's ...

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...

Alzheimer’s disease doesn’t have a cure, meaning no treatment can reverse the damage that’s already occurred in the brain. But that doesn’t mean life has to come to a screeching halt.

Prime Medicine (PRME) unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency, AATD, the next program within its liver franchise. Prime Medicine expects to file an ...

This award recognized LEQEMBI as “a world-first treatment for early AD developed in Japan which selectively binds to and clears neurotoxic substances (abnormal proteins), thereby reducing the rate of ...

March 18, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today ...